How much weight loss did CagriSema give in REDEFINE 9?
In REDEFINE 9, CagriSema gave 21.0% weight loss at 1.0 mg and 20.7% at 1.7 mg after 68 weeks, compared with 2.0% on placebo.
The figures show the effect if everyone stayed on treatment. REDEFINE 9 is a phase 3 study (the last testing phase before a possible approval), paid for by Novo and published on 14 November 2026 in The Lancet Diabetes & Endocrinology. It included 309 adults without diabetes with an average weight of 109.5 kg. They had obesity with a BMI (the ratio of weight to height) of 30 or above, or overweight with a BMI of 27 or above and at least one weight-related condition.[1]
The doses 1.0 mg and 1.7 mg are the amount of each of the two active substances. The weight loss is calculated as if everyone stayed on treatment.[1]
The participants were randomly assigned to a weekly injection of CagriSema 1.0 mg, 1.7 mg or placebo for 68 weeks, along with advice on diet and exercise. If you count all participants, including those who stopped along the way, the weight loss was 18.6% at 1.0 mg, 19.4% at 1.7 mg and 4.6% on placebo. At the same time, waist size went down by 17.5 cm at 1.0 mg, 17.2 cm at 1.7 mg and 3.6 cm on placebo.[2]
This is the first phase 3 study with doses lower than 2.4 mg, which is the highest dose in Novo's large studies. The study was not designed to compare the two doses with each other. Both doses did, however, give far greater weight loss than placebo, and the researchers point out that more dose steps can allow more flexible treatment.[2][1]
How quickly does CagriSema work?
In a later analysis of REDEFINE 1 at 2.4 mg, 67.8% of those on CagriSema had lost at least 5% of their weight after 8 weeks.
The analysis was presented on 15 November 2026 and looked at participants with an early effect, meaning at least 5% weight loss after 8 weeks. This group had lost an average of 25.4% after 68 weeks. Participants who got off to a slower start lost an average of 17.8% after 68 weeks.[3]
The figures should be read with caution, as the analysis was done after the study had ended. The researchers themselves say that it is a starting point for more research and not a rule for how to treat. In addition, the analysis only applies to the 2.4 mg dose and not to the lower doses.[3]
What side effects does CagriSema have?
The side effects of CagriSema came mostly from the stomach and gut, and 4.9% at 1.0 mg and 2.9% at 1.7 mg stopped because of them.
The side effects in REDEFINE 9 were usually mild to moderate and were similar to earlier studies of CagriSema. In the placebo group, 4.9% also stopped treatment along the way because of side effects. As a doctor, I always go through possible side effects thoroughly with you before any treatment, so you know what to expect.[2]
When will CagriSema come to Denmark?
CagriSema is not yet available in Denmark, and there is no date for Denmark, but according to Euroinvestor Novo expects to launch the medicine in 2027.
CagriSema is still a medicine being tested. In December 2025 Novo applied to the US medicines authorities for approval of the 2.4 mg dose and expects an answer in the fourth quarter of 2026. There is not yet a date for Denmark.[2][4]
Today Wegovy and Mounjaro are approved and can be prescribed if a doctor assesses that the treatment suits you. At Recepta the first doctor consultation is free, and the doctor follows up every 4 weeks.
Read also: Wegovy or Mounjaro: which is better? · How do you know if Wegovy is working for you?
Questions and answers about CagriSema
What is CagriSema?
What is the difference between CagriSema and Wegovy?
Which doses of CagriSema have been tested?
Sources
- Wharton S, Broholm C, Horn D, et al. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9). The Lancet Diabetes & Endocrinology, published online 14 November 2026. doi.org
- Novo Nordisk: Novo's investigational CagriSema demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial. Press release, 14 November 2026. prnewswire.com
- Novo Nordisk: Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1. Press release, 15 November 2026. prnewswire.com
- Geil A. Novos nye vægttabshåb viser vægttab på 21 pct. ved lavere doser. Euroinvestor, 16 November 2026. euroinvestor.dk